Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.


Journal Article (Review)

The role of circulating biomarkers in heart failure clinical trials has evolved in recent decades. Increasing evidence behind the use of natriuretic peptides, emergence of novel biomarkers, and increased emphasis on targeting therapies toward physiological basis of disease (so-called precision medicine) have all contributed to the continued expansion of biomarker use in heart failure clinical trials. We will explore the advantages and pitfalls encountered through the use of biomarkers in clinical trials as an inclusion criterion, toxicity marker, and end point. We will also review their role in providing insights into the mechanism of action of therapeutics and guiding therapy in the management of patients with heart failure.

Full Text

Duke Authors

Cited Authors

  • Ibrahim, NE; Gaggin, HK; Konstam, MA; Januzzi, JL

Published Date

  • September 2016

Published In

Volume / Issue

  • 9 / 9

PubMed ID

  • 27582282

Pubmed Central ID

  • 27582282

Electronic International Standard Serial Number (EISSN)

  • 1941-3297

Digital Object Identifier (DOI)

  • 10.1161/CIRCHEARTFAILURE.115.002528


  • eng

Conference Location

  • United States